Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 31% on Thursday . The stock traded as high as C$0.23 and last traded at C$0.19. Approximately 457,687 shares changed hands during mid-day trading, a decline of 13% from the average daily volume of 525,007 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Down 7.9 %
The firm has a market cap of C$25.50 million, a price-to-earnings ratio of -5.10 and a beta of 0.20. The firm’s fifty day moving average is C$0.20 and its two-hundred day moving average is C$0.12. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Trading Halts Explained
- DuPont’s Electronics Spinoff: The Start of Something Big
- ESG Stocks, What Investors Should Know
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
